| http://www.w3.org/ns/prov#value | - However, if payers, including private insurance companies from the U.S. cannot quantify improvements in glycemic control using HbA1c, then the more qualitative criteria must be used, and again, these factors such as quality-of-life ratings from patients with diabetes generally do not show much difference since insulin analogues have emerged, so unless there is a better way to analyze results, they
|
